Advertisement

Topics

Search Results for "Rituximab Patent"

01:42 EDT 29th April 2016 | BioPortfolio

Matching Channels

CD20 Antibodies

The chimeric anti-CD20 antibody rituximab (Rituxan & MabThera) from Biogen Idec and Genentech/Roche is one of the world’s commercially most successful antibodies (2007 sales of over US$ 5 bl...

Biosuperior Antibodies

After biosimilar versions of therapeutic proteins have become reality in Europe and in the US, now it’s the turn of therapeutic antibodies to be in the line of fire. Patents of the first wave of...

India

India, in the Asian subcontinent is the world’s fourth largest producer of pharmaceuticals, and is thought as one of the most promising biotech markets in the world. Several important steps ...

Tumor Necrosis Factor TNF Products

Tumor Necrosis Factor (TNF) and TNF receptor antagonists and agonists used to treat TNF-mediated inflammatory diseases such as rheumatoid arthritis or to treat cancer. TNF blockers are the commerc...

Matching News

Rituximab plus chemo may improve outcomes for ALL

Dr Maury talks to ecancertv at ASH 2015 about a randomised trial looking at rituximab in addition to standard chemotherapy to treat patients with acute lymphoblastic leukaemia. The study showed th...

Celltrion Expects Korea Rituximab Approval Despite Biogen Action

Biogen moves to halt Celltrion from selling a rituximab biosimilar in South Korea by seeking a patent scope confirmation trial as the South Korean firm gears up to launch its second biosimilar. But Ce...

Intrathecal rituximab for EBV-associated post-transplant lymphoproliferative disorder with central nervous system involvement unresponsive to intravenous rituximab-based treatments: a prospective study

Long-term Rituximab Maintenance for Follicular Lymphoma

After single-agent rituximab therapy for follicular lymphoma, long-term rituximab maintenance therapy significantly prolonged progression-free but not overall survival in the randomized controlled SAK...

Pivotal clinical trials for rituximab biosimilars

Biosimilars of Roche’s MabThera/Rituxan (rituximab), a chimeric monoclonal antibody are currently under development.

Rituximab + Chemo: New Standard of Care for BCP-ALL?

Adding rituximab to chemotherapy significantly improved event free survival in patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Medscape Medical News

The BAFFling effects of rituximab in lupus: danger ahead?

Ehrenstein and Wing assert that rituximab re-treatment can trigger a vicious circle of ever-rising levels of BAFF (B-cell-activating factor, also known as TNF ligand superfamily member 13B), increasin...

Russian biotech wins case against Genentech in patent dispute

The claim on Rituxan/MabThera (rituximab) intellectual property (IP) by Genentech, the biotech subsidiary…

Matching PubMed Articles

Patent Deployment Strategies and Patent Value in LED Industry.

This study applies two variables in the measurement of company patent deployment strategies: patent family depth and earn plan ratio. Patent family depth represents the degree to which certain fields ...

Patent Highlights June-July 2015.

A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.

Searching bioremediation patents through Cooperative Patent Classification (CPC).

Patent classification systems have traditionally evolved independently at each patent jurisdiction to classify patents handled by their examiners to be able to search previous patents while dealing wi...

Rituximab infusion-related toxicity in patients with chronic lymphocytic leukemia.

Rituximab in combination with chemotherapy is an effective treatment of patients (pts) with chronic lymphocytic leukemia (CLL). The most frequent adverse event of rituximab is infusion-related toxicit...

Rituximab for indolent lymphomas before and after allogeneic hematopoietic stem cell transplantation.

The most substantial advancement in the treatment of indolent B-cell non-Hodgkin lymphoma (NHL), since the advent of combination chemotherapy, has been the introduction of the monoclonal anti-CD20 ant...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement